المؤلفون: Burge M., Segelov E., Tebbutt N.C., Reece W.H.H., Price T., Molloy M.P., Marx G., Jones K., Gibbs P., Feeney K., Clarke S.J.

مصطلحات الفهرس: intestine fistula/si [Side Effect], intestine perforation/si [Side Effect], large intestine perforation/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, metastatic colorectal cancer/dt [Drug Therapy], mucosa inflammation/si [Side Effect], multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], neutrophil lymphocyte ratio, open study, overall survival, paresthesia/si [Side Effect], perianal abscess/si [Side Effect], peripheral neuropathy/si [Side Effect], phase 4 clinical trial, progression free survival, proteinuria/si [Side Effect], proteomics, rectum perforation/si [Side Effect], survival rate, treatment outcome, vomiting/si [Side Effect], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], capecitabine plus oxaliplatin/ct [Clinical Trial], capecitabine plus oxaliplatin/dt [Drug Therapy], proteome/ec [Endogenous Compound], capecitabine plus oxaliplatin/ae [Adverse Drug Reaction], abdominal pain/si [Side Effect], adult, aged, alopecia/si [Side Effect], anus fistula/si [Side Effect], article, cancer combination chemotherapy, cancer prognosis, carcinoma in situ/dt [Drug Therapy], constipation/si [Side Effect], controlled study, decreased appetite/si [Side Effect], diarrhea/si [Side Effect], digestive system perforation/si [Side Effect], drug safety, epistaxis/si [Side Effect], exploratory research, fatigue/si [Side Effect], female, gastroesophageal reflux/si [Side Effect], hand foot syndrome/si [Side Effect], human, hypertension/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29334
PLoS ONE
Click here for full text options
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
Click here for full text options
LibKey Link

المؤلفون: Burge M., Segelov E., Tebbutt N.C., Reece W.H.H., Price T., Molloy M.P., Marx G., Jones K., Gibbs P., Feeney K., Clarke S.J.

مصطلحات الفهرس: intestine fistula/si [Side Effect], intestine perforation/si [Side Effect], large intestine perforation/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, metastatic colorectal cancer/dt [Drug Therapy], mucosa inflammation/si [Side Effect], multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], neutrophil lymphocyte ratio, open study, overall survival, paresthesia/si [Side Effect], perianal abscess/si [Side Effect], peripheral neuropathy/si [Side Effect], phase 4 clinical trial, progression free survival, proteinuria/si [Side Effect], proteomics, rectum perforation/si [Side Effect], survival rate, treatment outcome, vomiting/si [Side Effect], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], capecitabine plus oxaliplatin/ct [Clinical Trial], capecitabine plus oxaliplatin/dt [Drug Therapy], proteome/ec [Endogenous Compound], capecitabine plus oxaliplatin/ae [Adverse Drug Reaction], abdominal pain/si [Side Effect], adult, aged, alopecia/si [Side Effect], anus fistula/si [Side Effect], article, cancer combination chemotherapy, cancer prognosis, carcinoma in situ/dt [Drug Therapy], constipation/si [Side Effect], controlled study, decreased appetite/si [Side Effect], diarrhea/si [Side Effect], digestive system perforation/si [Side Effect], drug safety, epistaxis/si [Side Effect], exploratory research, fatigue/si [Side Effect], female, gastroesophageal reflux/si [Side Effect], hand foot syndrome/si [Side Effect], human, hypertension/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29334
PLoS ONE
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
LibKey Link

المؤلفون: Ferguson M., Ashley D.M., Wood P.J., Strong R., McArthur G.A., Michael M., Algar E., Muscat A., Rigby L.

مصطلحات الفهرس: comparative study, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug tolerability, dyspnea/si [Side Effect], electrocardiogram, ependymoma/di [Diagnosis], ependymoma/dt [Drug Therapy], facial nerve disease/si [Side Effect], fatigue/si [Side Effect], gait disorder/si [Side Effect], headache/si [Side Effect], heart arrhythmia/si [Side Effect], heart supraventricular arrhythmia/si [Side Effect], histone acetylation, human, hydrocephalus/si [Side Effect], infection complication/si [Side Effect], insomnia/si [Side Effect], leukocyte count, limb pain/si [Side Effect], limb weakness/si [Side Effect], lymphocyte count, magnesium blood level, male, maximum tolerated dose, medulloblastoma/di [Diagnosis], medulloblastoma/dt [Drug Therapy], multicenter study, muscle weakness/si [Side Effect], musculoskeletal disease/si [Side Effect], nausea/si [Side Effect], neck pain/si [Side Effect], nephroblastoma/di [Diagnosis], nephroblastoma/dt [Drug Therapy], neuroblastoma/di [Diagnosis], neuroblastoma/dt [Drug Therapy], neutropenia/si [Side Effect], neutrophil count, nystagmus/si [Side Effect], pediatrics, peripheral blood mononuclear cell, personal experience, pharmacokinetic parameters, phase 1 clinical trial, platelet count, potassium blood level, priority journal, rhabdomyosarcoma/di [Diagnosis], rhabdomyosarcoma/dt [Drug Therapy], school child, seizure/si [Side Effect], side effect/si [Side Effect], sinus arrhythmia/si [Side Effect], skin disease/si [Side Effect], sodium blood level, solid malignant neoplasm/di [Diagnosis], solid malignant neoplasm/dt [Drug Therapy], stomach pain/si [Side Effect], supraventricular tachycardia/si [Side Effect], thrombocytopenia/si [Side Effect], time to maximum plasma concentration, time to treatment, urine retention/si [Side Effect], visual disorder/si [Side Effect], vomiting/si [Side Effect], Western blotting, wound dehiscence/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], albumin/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], bicarbonate/ec [Endogenous Compound], bilirubin/ec [Endogenous Compound], creatine kinase/ec [Endogenous Compound], creatinine/ec [Endogenous Compound], dexamethasone, hemoglobin/ec [Endogenous Compound], histone H3/ec [Endogenous Compound], histone H4/ec [Endogenous Compound], magnesium/ec [Endogenous Compound], panobinostat/ae [Adverse Drug Reaction], panobinostat/ct [Clinical Trial], panobinostat/dt [Drug Therapy], panobinostat/iv [Intravenous Drug Administration], panobinostat/pk [Pharmacokinetics], panobinostat/pd [Pharmacology], potassium/ec [Endogenous Compound], sodium/ec [Endogenous Compound], hypokalemia/si [Side Effect], female, fever/si [Side Effect], fracture/si [Side Effect], abdominal pain/si [Side Effect], abnormal laboratory result, adverse drug reaction, alkalosis/si [Side Effect], alopecia/si [Side Effect], anemia/si [Side Effect], antineoplastic activity, apnea/si [Side Effect], area under the curve, article, ataxia/si [Side Effect], body weight loss, cancer pain/si [Side Effect], central nervous system tumor/di [Diagnosis], central nervous system tumor/dt [Drug Therapy], child, clinical article, clinical evaluation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37032
Cancer Chemotherapy and Pharmacology
Click here for full text options
LibKey Link

المؤلفون: Strippoli G.F.M., Masson P., Craig J.C., Tong A., Singh-Grewal D., Flanc R.S., Roberts M.A., Webster A.C., Tunnicliffe D.J., Palmer S.C., Henderson L.

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

المؤلفون: Ferguson M., Ashley D.M., Wood P.J., Strong R., McArthur G.A., Michael M., Algar E., Muscat A., Rigby L.

مصطلحات الفهرس: comparative study, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug tolerability, dyspnea/si [Side Effect], electrocardiogram, ependymoma/di [Diagnosis], ependymoma/dt [Drug Therapy], facial nerve disease/si [Side Effect], fatigue/si [Side Effect], gait disorder/si [Side Effect], headache/si [Side Effect], heart arrhythmia/si [Side Effect], heart supraventricular arrhythmia/si [Side Effect], histone acetylation, human, hydrocephalus/si [Side Effect], infection complication/si [Side Effect], insomnia/si [Side Effect], leukocyte count, limb pain/si [Side Effect], limb weakness/si [Side Effect], lymphocyte count, magnesium blood level, male, maximum tolerated dose, medulloblastoma/di [Diagnosis], medulloblastoma/dt [Drug Therapy], multicenter study, muscle weakness/si [Side Effect], musculoskeletal disease/si [Side Effect], nausea/si [Side Effect], neck pain/si [Side Effect], nephroblastoma/di [Diagnosis], nephroblastoma/dt [Drug Therapy], neuroblastoma/di [Diagnosis], neuroblastoma/dt [Drug Therapy], neutropenia/si [Side Effect], neutrophil count, nystagmus/si [Side Effect], pediatrics, peripheral blood mononuclear cell, personal experience, pharmacokinetic parameters, phase 1 clinical trial, platelet count, potassium blood level, priority journal, rhabdomyosarcoma/di [Diagnosis], rhabdomyosarcoma/dt [Drug Therapy], school child, seizure/si [Side Effect], side effect/si [Side Effect], sinus arrhythmia/si [Side Effect], skin disease/si [Side Effect], sodium blood level, solid malignant neoplasm/di [Diagnosis], solid malignant neoplasm/dt [Drug Therapy], stomach pain/si [Side Effect], supraventricular tachycardia/si [Side Effect], thrombocytopenia/si [Side Effect], time to maximum plasma concentration, time to treatment, urine retention/si [Side Effect], visual disorder/si [Side Effect], vomiting/si [Side Effect], Western blotting, wound dehiscence/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], albumin/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], bicarbonate/ec [Endogenous Compound], bilirubin/ec [Endogenous Compound], creatine kinase/ec [Endogenous Compound], creatinine/ec [Endogenous Compound], dexamethasone, hemoglobin/ec [Endogenous Compound], histone H3/ec [Endogenous Compound], histone H4/ec [Endogenous Compound], magnesium/ec [Endogenous Compound], panobinostat/ae [Adverse Drug Reaction], panobinostat/ct [Clinical Trial], panobinostat/dt [Drug Therapy], panobinostat/iv [Intravenous Drug Administration], panobinostat/pk [Pharmacokinetics], panobinostat/pd [Pharmacology], potassium/ec [Endogenous Compound], sodium/ec [Endogenous Compound], hypokalemia/si [Side Effect], female, fever/si [Side Effect], fracture/si [Side Effect], abdominal pain/si [Side Effect], abnormal laboratory result, adverse drug reaction, alkalosis/si [Side Effect], alopecia/si [Side Effect], anemia/si [Side Effect], antineoplastic activity, apnea/si [Side Effect], area under the curve, article, ataxia/si [Side Effect], body weight loss, cancer pain/si [Side Effect], central nervous system tumor/di [Diagnosis], central nervous system tumor/dt [Drug Therapy], child, clinical article, clinical evaluation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37032
Cancer Chemotherapy and Pharmacology
Click here for full text options
LibKey Link

المؤلفون: Strippoli G.F.M., Masson P., Craig J.C., Tong A., Singh-Grewal D., Flanc R.S., Roberts M.A., Webster A.C., Tunnicliffe D.J., Palmer S.C., Henderson L.

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

المؤلفون: Shortt J., Ong T.C., Elhaddad A., Quach H., Pavlovsky C., Louw V.J., Shih L.-Y., Turkina A.G., Meillon L., Jin Y., Acharya S., Dalal D., Aurelio Salvino M., Lipton J.H., Hughes T.P., Munhoz E.

مصطلحات الفهرس: hypertransaminasemia/si [Side Effect], ischemic heart disease/si [Side Effect], leukopenia/si [Side Effect], liver toxicity/si [Side Effect], lung edema/si [Side Effect], lymphocytopenia/si [Side Effect], major clinical study, male, multicenter study (topic), nausea/si [Side Effect], neutropenia/si [Side Effect], overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], peripheral occlusive artery disease/si [Side Effect], phase 3 clinical trial (topic), pleura effusion/si [Side Effect], priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], retina vein occlusion/si [Side Effect], side effect/si [Side Effect], thrombocytopenia/si [Side Effect], thrombophlebitis/si [Side Effect], upper respiratory tract infection/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], BCR ABL protein/ec [Endogenous Compound], bilirubin/ec [Endogenous Compound], glucose/ec [Endogenous Compound], magnesium/ec [Endogenous Compound], nilotinib/ae [Adverse Drug Reaction], nilotinib/ct [Clinical Trial], nilotinib/dt [Drug Therapy], phosphate/ec [Endogenous Compound], sodium/ec [Endogenous Compound], triacylglycerol lipase/ec [Endogenous Compound], unclassified drug, BCR ABL1 protein/ec [Endogenous Compound], drug efficacy, adult, aged, alopecia/si [Side Effect], anemia/si [Side Effect], artery occlusion/si [Side Effect], article, bleeding/si [Side Effect], brain ischemia/si [Side Effect], cardiovascular disease/si [Side Effect], central nervous system disease/si [Side Effect], central nervous system hemorrhage/si [Side Effect], chronic myeloid leukemia/dt [Drug Therapy], constipation/si [Side Effect], coronary artery disease/si [Side Effect], deep vein thrombosis/si [Side Effect], drug dose escalation, drug dose reduction, drug safety, drug treatment failure, drug withdrawal, fatigue/si [Side Effect], female, follow up, gastrointestinal hemorrhage/si [Side Effect], headache/si [Side Effect], heart muscle ischemia/si [Side Effect], human, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38341
British Journal of Haematology
Click here for full text options
LibKey Link

المؤلفون: Shortt J., Ong T.C., Elhaddad A., Quach H., Pavlovsky C., Louw V.J., Shih L.-Y., Turkina A.G., Meillon L., Jin Y., Acharya S., Dalal D., Aurelio Salvino M., Lipton J.H., Hughes T.P., Munhoz E.

مصطلحات الفهرس: hypertransaminasemia/si [Side Effect], ischemic heart disease/si [Side Effect], leukopenia/si [Side Effect], liver toxicity/si [Side Effect], lung edema/si [Side Effect], lymphocytopenia/si [Side Effect], major clinical study, male, multicenter study (topic), nausea/si [Side Effect], neutropenia/si [Side Effect], overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], peripheral occlusive artery disease/si [Side Effect], phase 3 clinical trial (topic), pleura effusion/si [Side Effect], priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], retina vein occlusion/si [Side Effect], side effect/si [Side Effect], thrombocytopenia/si [Side Effect], thrombophlebitis/si [Side Effect], upper respiratory tract infection/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], BCR ABL protein/ec [Endogenous Compound], bilirubin/ec [Endogenous Compound], glucose/ec [Endogenous Compound], magnesium/ec [Endogenous Compound], nilotinib/ae [Adverse Drug Reaction], nilotinib/ct [Clinical Trial], nilotinib/dt [Drug Therapy], phosphate/ec [Endogenous Compound], sodium/ec [Endogenous Compound], triacylglycerol lipase/ec [Endogenous Compound], unclassified drug, BCR ABL1 protein/ec [Endogenous Compound], drug efficacy, adult, aged, alopecia/si [Side Effect], anemia/si [Side Effect], artery occlusion/si [Side Effect], article, bleeding/si [Side Effect], brain ischemia/si [Side Effect], cardiovascular disease/si [Side Effect], central nervous system disease/si [Side Effect], central nervous system hemorrhage/si [Side Effect], chronic myeloid leukemia/dt [Drug Therapy], constipation/si [Side Effect], coronary artery disease/si [Side Effect], deep vein thrombosis/si [Side Effect], drug dose escalation, drug dose reduction, drug safety, drug treatment failure, drug withdrawal, fatigue/si [Side Effect], female, follow up, gastrointestinal hemorrhage/si [Side Effect], headache/si [Side Effect], heart muscle ischemia/si [Side Effect], human, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38341
British Journal of Haematology
Click here for full text options
LibKey Link

المؤلفون: Roddy J., Rabusa C., Proudman S.M., Zochling J., Sahhar J., Youssef P., Tymms K., Sturgess A., Hill C.L., Owen C.E., Ngian G.-S., Elford K., Moore O.A., Stevens W., Nikpour M.

مصطلحات الفهرس: cohort analysis, mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/dt [Drug Therapy], systemic sclerosis, azathioprine/ae [Adverse Drug Reaction], azathioprine/dt [Drug Therapy], adult, alopecia/si [Side Effect], article, clinical article, cytopenia/si [Side Effect], drug efficacy, drug fatality/si [Side Effect], drug safety, drug tolerability, drug withdrawal, female, forced vital capacity, gastrointestinal symptom/si [Side Effect], human, infection/si [Side Effect], interstitial lung disease/co [Complication], interstitial lung disease/dt [Drug Therapy], liver dysfunction/si [Side Effect], male, priority journal, rash/si [Side Effect], skin cancer/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40458
Clinical and Experimental Rheumatology
Click here for full text options
LibKey Link

المؤلفون: Goss G., Johnson C., Capp A., Brooks S., Wain G., Kolodziej I., Veillard A.-S., Khaw P., O'Connell R., Creutzberg C.L., Stockler M.R., Mileshkin L., Blinman P.

مصطلحات الفهرس: sleep disorder/si [Side Effect], survival rate, survival time, urinary tract disease/si [Side Effect], vomiting/si [Side Effect], wellbeing, antineoplastic agent/ae [Adverse Drug Reaction], human, adjuvant chemotherapy, adult, aged, alopecia/si [Side Effect], anxiety disorder/si [Side Effect], article, cancer radiotherapy, cancer survival, diarrhea/si [Side Effect], disease severity, endometrium cancer, fatigue/si [Side Effect], female, hair loss/si [Side Effect], high risk population, irritability, major clinical study, married person, nausea/si [Side Effect], patient preference, priority journal, quality of life, questionnaire, randomized controlled trial, side effect/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39699
British Journal of Cancer
Click here for full text options
LibKey Link

المؤلفون: Ganju V., Underhill C., Shannon J.A., Gebski V., Tebbutt N.C., Price T.J., Ferraro D.A., Wong N., Veillard A.-S., Hall M., Sjoquist K.M., Pavlakis N., Strickland A., Varma S.C., Cooray P., Young R.

مصطلحات الفهرس: fluorouracil/cb [Drug Combination], panitumumab/cb [Drug Combination], panitumumab/dt [Drug Therapy], docetaxel/cb [Drug Combination], docetaxel/dt [Drug Therapy], fluorouracil/ae [Adverse Drug Reaction], fluorouracil/ct [Clinical Trial], fluorouracil/dt [Drug Therapy], panitumumab/ct [Clinical Trial], panitumumab/ae [Adverse Drug Reaction], acne/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], aged, alopecia/si [Side Effect], anorexia/si [Side Effect], article, cancer combination chemotherapy, cancer fatigue/si [Side Effect], cancer patient, cancer survival, chemotherapy induced emesis/si [Side Effect], controlled study, diarrhea/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug hypersensitivity/si [Side Effect], drug induced headache/si [Side Effect], drug safety, dysphagia/si [Side Effect], epiphora/si [Side Effect], esophagus cancer/dt [Drug Therapy], febrile neutropenia/si [Side Effect], female, follow up, hair loss/si [Side Effect], hand foot syndrome/si [Side Effect], hearing impairment/si [Side Effect], human, infection/si [Side Effect], major clinical study, male, motor neuropathy/si [Side Effect], multicenter study, multiple cycle treatment, nail disease/si [Side Effect], nausea/si [Side Effect], open study, overall survival, phase 2 clinical trial, priority journal, progression free survival, randomized controlled trial, sensory neuropathy/si [Side Effect], stomach cancer/dt [Drug Therapy], stomatitis/si [Side Effect], treatment response, capecitabine/ae [Adverse Drug Reaction], capecitabine/ct [Clinical Trial], capecitabine/cb [Drug Combination], capecitabine/dt [Drug Therapy], cisplatin/ae [Adverse Drug Reaction], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], docetaxel/ae [Adverse Drug Reaction], docetaxel/ct [Clinical Trial], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40040
British Journal of Cancer
Click here for full text options
LibKey Link

المؤلفون: Doyle A., Nicoll A., Lubel J., Gow P.J., Arachchi N., Fink M.A., Roberts S., Kemp W., Kronborg I., Bell S., Strasser S.I., Hong T., Varma P., Knight V., Dev A., Mohsen W., Ryan M., Rodov M., Gill R., Marsh P.

مصطلحات الفهرس: metastasis, mouth ulcer/si [Side Effect], multicenter study (topic), nausea/si [Side Effect], overall survival, priority journal, rash/si [Side Effect], retrospective study, side effect/si [Side Effect], weight reduction, alpha fetoprotein/ec [Endogenous Compound], sorafenib/ae [Adverse Drug Reaction], sorafenib/ct [Clinical Trial], sorafenib/dt [Drug Therapy], female, abdominal pain/si [Side Effect], adult, aged, alopecia/si [Side Effect], alpha fetoprotein blood level, anorexia/si [Side Effect], article, Australian, cancer chemotherapy, cancer mortality, cancer patient, cancer survival, Caucasian, Child Pugh score, cohort analysis, controlled study, diarrhea/si [Side Effect], drug dose reduction, drug withdrawal, ethnicity, fatigue/si [Side Effect], follow up, functional status, hand foot syndrome/si [Side Effect], human, hypertension/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], major clinical study, male, median survival time, medical record review, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39593
Scandinavian Journal of Gastroenterology
Click here for full text options
LibKey Link

المؤلفون: Ryan C., Woodward N., White M., Pugliano L., Tsoi D.

مصطلحات الفهرس: drug safety, drug tolerability, febrile neutropenia/si [Side Effect], human, infusion related reaction/si [Side Effect], leukopenia/si [Side Effect], liver dysfunction, managed care, nail infection/si [Side Effect], neutropenia/si [Side Effect], overall survival, patient identification, peripheral edema/si [Side Effect], peripheral neuropathy/si [Side Effect], priority journal, progression free survival, quality of life, rash/si [Side Effect], skin infection/si [Side Effect], treatment outcome, docetaxel/ae [Adverse Drug Reaction], docetaxel/cb [Drug Combination], docetaxel/dt [Drug Therapy], loperamide/dt [Drug Therapy], paclitaxel/ae [Adverse Drug Reaction], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], pertuzumab/ae [Adverse Drug Reaction], pertuzumab/cb [Drug Combination], pertuzumab/dt [Drug Therapy], trastuzumab/ae [Adverse Drug Reaction], trastuzumab/cb [Drug Combination], trastuzumab/dt [Drug Therapy], trastuzumab emtansine/ae [Adverse Drug Reaction], trastuzumab emtansine/dt [Drug Therapy], patient selection, alopecia/si [Side Effect], article, Asian, Australian, breast cancer/dt [Drug Therapy], cancer adjuvant therapy, cancer growth, cancer recurrence, cancer survival, cardiotoxicity/si [Side Effect], central nervous system metastasis, clinical practice, diarrhea/dt [Drug Therapy], diarrhea/si [Side Effect], drug choice, drug efficacy, drug response, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39861
Asia-Pacific Journal of Clinical Oncology
Click here for full text options
LibKey Link

المؤلفون: Goss G., Johnson C., Capp A., Brooks S., Wain G., Kolodziej I., Veillard A.-S., Khaw P., O'Connell R., Creutzberg C.L., Stockler M.R., Mileshkin L., Blinman P.

مصطلحات الفهرس: sleep disorder/si [Side Effect], survival rate, survival time, urinary tract disease/si [Side Effect], vomiting/si [Side Effect], wellbeing, antineoplastic agent/ae [Adverse Drug Reaction], human, adjuvant chemotherapy, adult, aged, alopecia/si [Side Effect], anxiety disorder/si [Side Effect], article, cancer radiotherapy, cancer survival, diarrhea/si [Side Effect], disease severity, endometrium cancer, fatigue/si [Side Effect], female, hair loss/si [Side Effect], high risk population, irritability, major clinical study, married person, nausea/si [Side Effect], patient preference, priority journal, quality of life, questionnaire, randomized controlled trial, side effect/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39699
British Journal of Cancer
LibKey Link

المؤلفون: Roddy J., Rabusa C., Proudman S.M., Zochling J., Sahhar J., Youssef P., Tymms K., Sturgess A., Hill C.L., Owen C.E., Ngian G.-S., Elford K., Moore O.A., Stevens W., Nikpour M.

مصطلحات الفهرس: cohort analysis, mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/dt [Drug Therapy], systemic sclerosis, azathioprine/ae [Adverse Drug Reaction], azathioprine/dt [Drug Therapy], adult, alopecia/si [Side Effect], article, clinical article, cytopenia/si [Side Effect], drug efficacy, drug fatality/si [Side Effect], drug safety, drug tolerability, drug withdrawal, female, forced vital capacity, gastrointestinal symptom/si [Side Effect], human, infection/si [Side Effect], interstitial lung disease/co [Complication], interstitial lung disease/dt [Drug Therapy], liver dysfunction/si [Side Effect], male, priority journal, rash/si [Side Effect], skin cancer/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40458
Clinical and Experimental Rheumatology
LibKey Link

المؤلفون: Ganju V., Underhill C., Shannon J.A., Gebski V., Tebbutt N.C., Price T.J., Ferraro D.A., Wong N., Veillard A.-S., Hall M., Sjoquist K.M., Pavlakis N., Strickland A., Varma S.C., Cooray P., Young R.

مصطلحات الفهرس: fluorouracil/cb [Drug Combination], panitumumab/cb [Drug Combination], panitumumab/dt [Drug Therapy], docetaxel/cb [Drug Combination], docetaxel/dt [Drug Therapy], fluorouracil/ae [Adverse Drug Reaction], fluorouracil/ct [Clinical Trial], fluorouracil/dt [Drug Therapy], panitumumab/ct [Clinical Trial], panitumumab/ae [Adverse Drug Reaction], acne/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], aged, alopecia/si [Side Effect], anorexia/si [Side Effect], article, cancer combination chemotherapy, cancer fatigue/si [Side Effect], cancer patient, cancer survival, chemotherapy induced emesis/si [Side Effect], controlled study, diarrhea/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug hypersensitivity/si [Side Effect], drug induced headache/si [Side Effect], drug safety, dysphagia/si [Side Effect], epiphora/si [Side Effect], esophagus cancer/dt [Drug Therapy], febrile neutropenia/si [Side Effect], female, follow up, hair loss/si [Side Effect], hand foot syndrome/si [Side Effect], hearing impairment/si [Side Effect], human, infection/si [Side Effect], major clinical study, male, motor neuropathy/si [Side Effect], multicenter study, multiple cycle treatment, nail disease/si [Side Effect], nausea/si [Side Effect], open study, overall survival, phase 2 clinical trial, priority journal, progression free survival, randomized controlled trial, sensory neuropathy/si [Side Effect], stomach cancer/dt [Drug Therapy], stomatitis/si [Side Effect], treatment response, capecitabine/ae [Adverse Drug Reaction], capecitabine/ct [Clinical Trial], capecitabine/cb [Drug Combination], capecitabine/dt [Drug Therapy], cisplatin/ae [Adverse Drug Reaction], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], docetaxel/ae [Adverse Drug Reaction], docetaxel/ct [Clinical Trial], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40040
British Journal of Cancer
LibKey Link

المؤلفون: Doyle A., Nicoll A., Lubel J., Gow P.J., Arachchi N., Fink M.A., Roberts S., Kemp W., Kronborg I., Bell S., Strasser S.I., Hong T., Varma P., Knight V., Dev A., Mohsen W., Ryan M., Rodov M., Gill R., Marsh P.

مصطلحات الفهرس: metastasis, mouth ulcer/si [Side Effect], multicenter study (topic), nausea/si [Side Effect], overall survival, priority journal, rash/si [Side Effect], retrospective study, side effect/si [Side Effect], weight reduction, alpha fetoprotein/ec [Endogenous Compound], sorafenib/ae [Adverse Drug Reaction], sorafenib/ct [Clinical Trial], sorafenib/dt [Drug Therapy], female, abdominal pain/si [Side Effect], adult, aged, alopecia/si [Side Effect], alpha fetoprotein blood level, anorexia/si [Side Effect], article, Australian, cancer chemotherapy, cancer mortality, cancer patient, cancer survival, Caucasian, Child Pugh score, cohort analysis, controlled study, diarrhea/si [Side Effect], drug dose reduction, drug withdrawal, ethnicity, fatigue/si [Side Effect], follow up, functional status, hand foot syndrome/si [Side Effect], human, hypertension/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], major clinical study, male, median survival time, medical record review, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39593
Scandinavian Journal of Gastroenterology
LibKey Link

المؤلفون: Ryan C., Woodward N., White M., Pugliano L., Tsoi D.

مصطلحات الفهرس: drug safety, drug tolerability, febrile neutropenia/si [Side Effect], human, infusion related reaction/si [Side Effect], leukopenia/si [Side Effect], liver dysfunction, managed care, nail infection/si [Side Effect], neutropenia/si [Side Effect], overall survival, patient identification, peripheral edema/si [Side Effect], peripheral neuropathy/si [Side Effect], priority journal, progression free survival, quality of life, rash/si [Side Effect], skin infection/si [Side Effect], treatment outcome, docetaxel/ae [Adverse Drug Reaction], docetaxel/cb [Drug Combination], docetaxel/dt [Drug Therapy], loperamide/dt [Drug Therapy], paclitaxel/ae [Adverse Drug Reaction], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], pertuzumab/ae [Adverse Drug Reaction], pertuzumab/cb [Drug Combination], pertuzumab/dt [Drug Therapy], trastuzumab/ae [Adverse Drug Reaction], trastuzumab/cb [Drug Combination], trastuzumab/dt [Drug Therapy], trastuzumab emtansine/ae [Adverse Drug Reaction], trastuzumab emtansine/dt [Drug Therapy], patient selection, alopecia/si [Side Effect], article, Asian, Australian, breast cancer/dt [Drug Therapy], cancer adjuvant therapy, cancer growth, cancer recurrence, cancer survival, cardiotoxicity/si [Side Effect], central nervous system metastasis, clinical practice, diarrhea/dt [Drug Therapy], diarrhea/si [Side Effect], drug choice, drug efficacy, drug response, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39861
Asia-Pacific Journal of Clinical Oncology
LibKey Link